【招银国际】 Breakup with Biogen on orelabrutinib for the treatment of autoimmune diseases.pdf

–Consistent results of orelabrutinib for MS

Biogen returned global rights of Orelabrutinib

Eyes on next steps of orelabrutinib for MS